Ovarian / Fallopian / Peritoneal

- Relapsed or Refractory Intolerant to Standard Care
  - CCT5048 Phase I Open Label Dose Escalation Study of CRX100 in Advanced Solid Tumors
    - PI: Dorigo
    - Sponsor: BioEclipse Therapeutics
    - 1st Priority
  - VAR0243 Phase II Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent and in Combination Therapy in Advanced Solid Tumors
    - PI: Telli
    - Sponsor: Blueprint Medicines Corporation
- Advanced Solid Tumors
  - Recurrent or Refractory
    - ECOG-ACRIN-EAY191-N4 Randomized Trial of Selumeti Neb & Olaparib or Selumetinib Alone in Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A COMBOMATCH Treatment Trial
      - PI: Chow
      - Sponsor: National Cancer Institute (NCI)
      - 2nd Priority
  - Recurrent
    - GYNOPF0018 Phase III Study of Relaxoril in Combination w/ Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA)
      - PI: Dorigo
      - Sponsor: Concept Therapeutics Incorporated
  - Platinum Resistant
    - GYNOPF0019 Phase II Trial of Niraparib in Recurrent Ovarian Granulosa Cell Tumors
      - PI: Dorigo
      - Sponsor: SpringWorks Therapeutics
      - 2nd Priority
  - Platinum Resistant or Refractory
    - Part 2A - (Only if CCNE1 Amplified; Excluding Carcinosarcoma)
      - VAR0243 Phase III Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent and in Combination Therapy in Advanced Solid Tumors
        - PI: Telli
        - Sponsor: Blueprint Medicines Corporation
  - Ovarian Granulosa Cell Tumors
    - CCT5088 Phase II Trial of Niraparib in Recurrent Ovarian Granulosa Cell Tumors
      - PI: Dorigo
      - Sponsor: SpringWorks Therapeutics
      - 2nd Priority
  - Platinum Sensitive
    - GYNova0057 Phase II Study of Mirvetuximab Soravatansine in Combo w/ Bevacizumab vs Bevacizumab Alone as Maintenance Therapy in FR Alpha-Positive Recurrent Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab
      - PI: Berek
      - Sponsor: Immunogen, Inc.